Deals this week: Circle Pharma, Multiple Myeloma Research Foundation (MMRF), Sinchuan Languang Development

15th September 2016 (Last Updated September 15th, 2016 18:30)

Circle Pharma and Pfizer have entered an agreement to develop a screening library of macrocyclic peptides.

Circle Pharma and Pfizer have entered an agreement to develop a screening library of macrocyclic peptides.

According to the agreement, Circle Pharma will be responsible to provide computational design and synthetic chemistry platform and develop physical screening of specific macrocyclic peptides.

With non-exclusive rights to the screen library against specific targets, Pfizer will support the development of the library.

The agreement enables the two partners to develop a library that will contain hundreds of macrocycles to derive disease processes and create derivative libraries designed specifically for a therapeutic target class.

Multiple Myeloma Research Foundation (MMRF) and Memorial Sloan Kettering Cancer Centre (MSKCC) have entered a co-development agreement to advance the clinical trials on multiple myeloma and develop precision medicine for myeloma patients.

The agreement enables the partners to launch new clinical trials for multiple myeloma, further develop patient’s genetic fingerprints of the disease during diagnosis, and define myeloma subclones during therapy.

"With non-exclusive rights to screen library against specific targets, Pfizer will support the development of the library."

Pharmaceutical manufacturer and distributor Sinchuan Languang Development plans to issue bonds due 2021.

The company expects to raise up to $448.5m from the offering.

Agios Pharmaceuticals plans to raise gross proceeds of up to $150m through the public offering of shares of its common stock.

J.P.Morgan Securities and Goldman, Sachs & Co are acting as book running managers, while Wilmer Cutler Pickering Hale and Dorr is acting as legal adviser for the offering.

The company plans to invest the funds to increase the working capital and for general corporate purposes.


Image: Circle Pharma and Pfizer have entered an agreement to develop screening library of macrocyclic peptides. Photo: courtesy of Neruru via Wikipedia.